UPDATE 1-Further promising data seen with Biogen Alzheimer's drug -study

Dec 8 (Reuters) - Gradually increasing the dose of Biogen Inc's experimental Alzheimer's disease drug appeared to cause less risk of brain swelling than higher fixed doses, according to interim 12-month results from a small study released on Thursday.